标题
Pushing estrogen receptor around in breast cancer
作者
关键词
-
出版物
ENDOCRINE-RELATED CANCER
Volume 23, Issue 12, Pages T227-T241
出版商
Bioscientifica
发表日期
2016-10-12
DOI
10.1530/erc-16-0427
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Abstract S6-01:PIK3CAstatus in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR+/HER2– advanced breast cancer (BC): First results from the randomized, phase III BELLE-2 trial:
- (2016) J Baselga et al. CANCER RESEARCH
- Window-of-Opportunity Trials in the Preoperative Setting: Insights Into Drug Development for Estrogen Receptor–Positive Breast Cancer
- (2016) Matthew P. Goetz et al. JOURNAL OF CLINICAL ONCOLOGY
- PlasmaESR1Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer
- (2016) Charlotte Fribbens et al. JOURNAL OF CLINICAL ONCOLOGY
- Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial
- (2016) Ian E Krop et al. LANCET ONCOLOGY
- Cooperative Dynamics of AR and ER Activity in Breast Cancer
- (2016) N. C. D'Amato et al. MOLECULAR CANCER RESEARCH
- Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant
- (2016) Jill M. Spoerke et al. Nature Communications
- Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer
- (2016) Sarat Chandarlapaty et al. JAMA Oncology
- Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer
- (2015) J. O'Shaughnessy et al. ANNALS OF ONCOLOGY
- St. Gallen endocrine response classes predict recurrence rates over time
- (2015) R.H.T. Koornstra et al. BREAST
- Abstract P1-13-04: Enobosarm for the treatment of metastatic, estrogen and androgen receptor positive, breast cancer. Final results of the primary endpoint and current progression free survival
- (2015) Beth Overmoyer et al. CANCER RESEARCH
- The intracrinology of breast cancer
- (2015) Keely May McNamara et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials
- (2015) LANCET
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
- (2015) Richard S Finn et al. LANCET ONCOLOGY
- Progesterone receptor modulates ERα action in breast cancer
- (2015) Hisham Mohammed et al. NATURE
- ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer
- (2015) Rinath Jeselsohn et al. Nature Reviews Clinical Oncology
- Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
- (2015) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting the Androgen Receptor in Breast Cancer
- (2015) KeeMing Chia et al. Current Oncology Reports
- DNA methylation of oestrogen-regulated enhancers defines endocrine sensitivity in breast cancer
- (2015) Andrew Stone et al. Nature Communications
- 10P * A PHASE 1 OPEN-LABEL STUDY EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ENZALUTAMIDE ALONE OR COMBINED WITH AN AROMATASE INHIBITOR IN WOMEN WITH ADVANCED BREAST CANCER
- (2014) T. A. Traina et al. ANNALS OF ONCOLOGY
- Activity of megestrol acetate in postmenopausal women with advanced breast cancer after nonsteroidal aromatase inhibitor failure: a phase II trial†
- (2014) J. Bines et al. ANNALS OF ONCOLOGY
- Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†
- (2014) M. Piccart et al. ANNALS OF ONCOLOGY
- Estrogen receptor (ER) α mutations in breast cancer: hidden in plain sight
- (2014) Suzanne A. W. Fuqua et al. BREAST CANCER RESEARCH AND TREATMENT
- AR collaborates with ERα in aromatase inhibitor-resistant breast cancer
- (2014) Yassine Rechoum et al. BREAST CANCER RESEARCH AND TREATMENT
- Complexities of androgen receptor signalling in breast cancer
- (2014) Keely M McNamara et al. ENDOCRINE-RELATED CANCER
- Increased androgen receptor activity and cell proliferation in aromatase inhibitor-resistant breast carcinoma
- (2014) Rika Fujii et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Selective androgen receptor modulators as improved androgen therapy for advanced breast cancer
- (2014) Christopher C. Coss et al. STEROIDS
- Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer
- (2013) W. Jonat et al. ANNALS OF ONCOLOGY
- A phase I dose escalation study to determine the optimal biological dose of irosustat, an oral steroid sulfatase inhibitor, in postmenopausal women with estrogen receptor-positive breast cancer
- (2013) R. Charles Coombes et al. BREAST CANCER RESEARCH AND TREATMENT
- Progesterone receptor expression is an independent prognostic variable in early breast cancer: a population-based study
- (2013) C A Purdie et al. BRITISH JOURNAL OF CANCER
- Expression of androgen receptor and its phosphorylated forms in breast cancer progression
- (2013) Qinghu Ren et al. CANCER
- Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer
- (2013) A. Gucalp et al. CLINICAL CANCER RESEARCH
- Androgen receptor expression is a predictive marker in chemotherapy-treated patients with endocrine receptor-positive primary breast cancers
- (2013) Isabell Witzel et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Effect of an investigational CYP17A1 inhibitor, orteronel (TAK-700), on estrogen- and corticoid-synthesis pathways in hypophysectomized female rats and on the serum estradiol levels in female cynomolgus monkeys
- (2013) Masuo Yamaoka et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- An International Ki67 Reproducibility Study
- (2013) Mei-Yin C. Polley et al. JNCI-Journal of the National Cancer Institute
- Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial
- (2013) Adrian S Dobs et al. LANCET ONCOLOGY
- ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
- (2013) Weiyi Toy et al. NATURE GENETICS
- Activating ESR1 mutations in hormone-resistant metastatic breast cancer
- (2013) Dan R Robinson et al. NATURE GENETICS
- Reduced Androgen Receptor Expression Accelerates the Onset of ERBB2 Induced Breast Tumors in Female Mice
- (2013) Myles C. Hodgson et al. PLoS One
- Endogenous Purification Reveals GREB1 as a Key Estrogen Receptor Regulatory Factor
- (2013) Hisham Mohammed et al. Cell Reports
- Mechanisms of estrogen-independent breast cancer growth driven by low estrogen concentrations are unique versus complete estrogen deprivation
- (2012) Matthew J. Sikora et al. BREAST CANCER RESEARCH AND TREATMENT
- Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’ study
- (2012) John F. R. Robertson et al. BREAST CANCER RESEARCH AND TREATMENT
- Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures
- (2012) Peter Kabos et al. BREAST CANCER RESEARCH AND TREATMENT
- AIB1:ER Transcriptional Activity Is Selectively Enhanced in Aromatase Inhibitor-Resistant Breast Cancer Cells
- (2012) J. O'Hara et al. CLINICAL CANCER RESEARCH
- An androgen receptor mutation in the MDA-MB-453 cell line model of molecular apocrine breast cancer compromises receptor activity
- (2012) Nicole L Moore et al. ENDOCRINE-RELATED CANCER
- Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study
- (2012) Thomas Bachelot et al. JOURNAL OF CLINICAL ONCOLOGY
- Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: Effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys
- (2012) Masuo Yamaoka et al. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY
- Minireview: The Androgen Receptor in Breast Tissues: Growth Inhibitor, Tumor Suppressor, Oncogene?
- (2012) T. E. Hickey et al. MOLECULAR ENDOCRINOLOGY
- Whole-genome analysis informs breast cancer response to aromatase inhibition
- (2012) Matthew J. Ellis et al. NATURE
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
- (2012) Christina Curtis et al. NATURE
- Combination Anastrozole and Fulvestrant in Metastatic Breast Cancer
- (2012) Rita S. Mehta et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical importance of androgen receptor in breast cancer patients treated with adjuvant tamoxifen monotherapy
- (2012) Naoko Honma et al. Breast Cancer
- Androgen Resistance in Female Mice Increases Susceptibility to DMBA-Induced Mammary Tumors
- (2012) Ulla Simanainen et al. Hormones & Cancer
- Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer
- (2011) Tomohiro Kaku et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy
- (2011) Sibylle Loibl et al. BREAST CANCER RESEARCH AND TREATMENT
- Targeting Androgen Receptor in Estrogen Receptor-Negative Breast Cancer
- (2011) Min Ni et al. CANCER CELL
- Androgen Receptor Expression and Breast Cancer Survival in Postmenopausal Women
- (2011) R. Hu et al. CLINICAL CANCER RESEARCH
- Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1
- (2011) Jessica L L Robinson et al. EMBO JOURNAL
- Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer
- (2011) C. Thangavel et al. ENDOCRINE-RELATED CANCER
- Differential Effects of Exogenous Androgen and an Androgen Receptor Antagonist in the Peri- and Postpubertal Murine Mammary Gland
- (2011) A. A. Peters et al. ENDOCRINOLOGY
- Irosustat: a first-generation steroid sulfatase inhibitor in breast cancer
- (2011) Carlo Palmieri et al. Expert Review of Anticancer Therapy
- Androgen receptor expression is usually maintained in initial surgically resected breast cancer metastases but is often lost in end-stage metastases found at autopsy
- (2011) Ashley Cimino-Mathews et al. HUMAN PATHOLOGY
- Single-Injection Depot Progesterone Before Surgery and Survival in Women With Operable Breast Cancer: A Randomized Controlled Trial
- (2011) Rajendra Badwe et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer
- (2011) Jack Cuzick et al. JOURNAL OF CLINICAL ONCOLOGY
- Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study
- (2011) Laura C Collins et al. MODERN PATHOLOGY
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial
- (2011) James T. Dalton et al. Journal of Cachexia Sarcopenia and Muscle
- Expression of androgen receptor in breast cancer and its significance as a prognostic factor
- (2010) Q. Yu et al. ANNALS OF ONCOLOGY
- Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers
- (2010) Isabella Castellano et al. BREAST CANCER RESEARCH AND TREATMENT
- Phase II trial of exemestane in combination with fulvestrant in postmenopausal women with hormone responsive advanced breast cancer: no evidence of a pharmacokinetic interaction between exemestane and fulvestrant.
- (2010) E Mrozek et al. CANCER RESEARCH
- FOXA1 is a key determinant of estrogen receptor function and endocrine response
- (2010) Antoni Hurtado et al. NATURE GENETICS
- Androgen receptor is frequently expressed in HER2-positive, ER/PR-negative breast cancers
- (2010) Donata Micello et al. VIRCHOWS ARCHIV
- Additive endocrine therapy for advanced breast cancer – back to the future
- (2009) Per Eystein Lønning ACTA ONCOLOGICA
- Expression of androgen receptors in primary breast cancer
- (2009) S. Park et al. ANNALS OF ONCOLOGY
- Risk of gynecological cancers in users of estradiol/dydrogesterone or other HRT preparations
- (2009) C. Schneider et al. CLIMACTERIC
- Androgen Receptor Levels and Association with PIK3CA Mutations and Prognosis in Breast Cancer
- (2009) A. M. Gonzalez-Angulo et al. CLINICAL CANCER RESEARCH
- Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen
- (2009) Mitch Dowsett et al. JOURNAL OF CLINICAL ONCOLOGY
- Nonsteroidal Selective Androgen Receptor Modulators (SARMs): Dissociating the Anabolic and Androgenic Activities of the Androgen Receptor for Therapeutic Benefit
- (2009) Michael L. Mohler et al. JOURNAL OF MEDICINAL CHEMISTRY
- Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation
- (2009) Leo A Niemeier et al. MODERN PATHOLOGY
- Structural basis for androgen specificity and oestrogen synthesis in human aromatase
- (2009) Debashis Ghosh et al. NATURE
- Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
- (2009) C. Tran et al. SCIENCE
- Tamoxifen for one year versus two years versus 6 months of Tamoxifen and 6 months of megestrol acetate: A randomized comparison in postmenopausal patients with high-risk breast cancer (DBCG 89C)
- (2008) Jørn Andersen et al. ACTA ONCOLOGICA
- The androgen metabolite 5α-androstane-3β,17β-diol (3βAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance
- (2008) Matthew J. Sikora et al. BREAST CANCER RESEARCH AND TREATMENT
- Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial
- (2008) LANCET ONCOLOGY
- Steroidal Androgens and Nonsteroidal, Tissue-Selective Androgen Receptor Modulator, S-22, Regulate Androgen Receptor Function through Distinct Genomic and Nongenomic Signaling Pathways
- (2008) Ramesh Narayanan et al. MOLECULAR ENDOCRINOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started